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The carboxy-terminal domain (CTD) of RNA poly-
merase II (Pol II) consists of heptad repeats with
the consensus motif Y1-S2-P3-T4-S5-P6-S7. Dynamic
phosphorylation of the CTD coordinates Pol II pro-
gression through the transcription cycle. Here, we
use genetic and mass spectrometric approaches to
directly detect and map phosphosites along the
entire CTD. We confirm phosphorylation of CTD res-
idues Y1, S2, T4, S5, and S7 in mammalian and yeast
cells. Although specific phosphorylation signatures
dominate, adjacent CTD repeats can be differently
phosphorylated, leading to a high variation of coex-
isting phosphosites in mono- and di-heptad CTD re-
peats. Inhibition of CDK9 kinase specifically reduces
S2 phosphorylation levels within the CTD.
INTRODUCTION
The carboxy-terminal domain (CTD) of the largest subunit (Rpb1)
of RNA polymerase II (Pol II) coordinates the transcription
cycle and gene expression (Bentley, 2014; Buratowski, 2009;
Corden, 2013; Egloff et al., 2012; Eick and Geyer, 2013).
The CTD consists of tandem heptad repeats with the
consensus sequence tyrosine-serine-proline-threonine-serine-
proline-serine (Y1S2P3T4S5P6S7) and forms a flexible, tail-like
extension from the catalytic core of Pol II with regions that are
proximal and distal to the Pol II surface (Cramer et al., 2001).
The CTD interacts with a wide range of nuclear factors based
on its dynamic plasticity and diversity of binding surfaces (Jas-
novidova and Stefl, 2013; Meinhart et al., 2005; Phatnani and
Greenleaf, 2006) generated by differential phosphorylation at
multiple sites, a phenomenon that was referred to as the ‘‘CTD
code’’ (Buratowski, 2003, 2009).
Monoclonal antibodies have been used to study in vivo the
potentially phosphorylated CTD amino acids (Y1, S2, T4, S5,
and S7) (Chapman et al., 2007; Descostes et al., 2014; EgloffMoet al., 2007; Hintermair et al., 2012; Hsin et al., 2011; Lu et al.,
1992; Mayer et al., 2012; Zhang and Corden, 1991). However,
the epitopes detected by antibodies can be masked by proteins
or modifications at neighboring sites. Therefore, the effective-
ness of antibodies in western blot or ChIP analysis reflects the
number of accessible CTD phosphorylation marks, but not
the total number of phosphorylations. Most importantly, CTD
phospho-specific antibodies do not provide any heptad (loca-
tion)-specific information of CTD phosphorylation. Due to these
limitations, the principles and patterns of CTD phosphorylation
remained elusive. Are all 52 CTD repeats phosphorylated in vivo?
What is the frequency of mono- and double-phosphorylated
heptad repeats? Do specific double-phospho signatures prevail
within neighboring CTD residues? Do mammals and yeast show
differences in signatures?What does the phosphorylation profile
of all 52 CTD repeats look like? Do CTD kinases introduce phos-
phosite-specific changes in CTD?
Within this study, we developed a reliable protocol for map-
ping heptad-specific phosphosites within the entire CTD of Pol
II in yeast and mammals, combining genetic manipulation of
the CTD with mass spectrometry (MS). This work provides in-
sights into the abundance and spatial patterns found among
the five different CTD phosphoresidues in vivo.RESULTS
Design, Stable Expression, and Purification of CTD
Variants for Subsequent MS Analysis
Due to its amino acid sequence, the bottom-up MS analysis of
the CTD was so far hampered by the difficulty to digest the
CTD into amenable peptides. The proximal part of the mamma-
lian CTD contains only heptads with the canonical sequence,
thus lacking the basic residues lysine (K) and arginine (R) that
are required for trypsin cleavage. In contrast, K and R residues
can be found in the less conserved, distal part of mammalian
CTD (Figure S1A), rendering these regions accessible to trypsin
cleavage and MS analysis (Figures 1A and 1B).
To generate tryptic peptides covering the complete CTD, we
established cell lines, which express CTD variants of Pol II con-




Figure 1. Newly Designed CTD Variants
Lead to 100% CTD Sequence Coverage by
MS Analysis
(A) Scheme of themapped phosphosites within the
CTD of WTrec, CTD variants M1 and M3. CTD
residues are shown by squares. Red: identified
phosphoresidue; blue: residue covered in the
analysis; gray: non-p-acceptor residue; black:
excluded phosphoresidue due to potential Y1P
mis-assignment; and yellow: residue not covered
in analysis.
(B) Schematic overview of all 52 repeats of WTrec,
CTD variants M1 and M3 including consensus and
non-consensus repeats, as well as mutated re-
peats with newly introduced trypsin cleavage sites.
(C) (Left) CTD sequence of variant M1. Red letters:
amino acid substitution or addition. Blue letters:
non-consensus residues. (Right) List of tryptic CTD
peptides of variant M1. Numbers indicate CTD
repeats covered by the corresponding peptide.
(D) Western blot analysis of purified Rpb1-HA
of CTD variant M1 using CTD phospho-specific
antibodies.
(E) Coomassie-stained SDS-PAGE of purified
Rpb1-M1-HA. M, marker.
See also Figure S1.heptad repeats in the proximal part of the mammalian CTD (Fig-
ure 1B). To distinguish the detected peptides in the MS, it is
essential that all peptides have a unique amino acid composi-
tion. Consequently, additional amino acids next to the
substituted K and R residues were strategically inserted. In total,
five CTD variants were designed that differed in the resulting
tryptic peptides (Figures 1C and S1B). CTD variant M1 for
example, carries 15 lysine or arginine substitutions and several
alanine, leucine, and valine additions (Figure 1C). The tryptic
cleavage of CTD variant M1 resulted in 25 peptides with unique
amino acid composition (Figure 1C). To reduce the risk of
designing non-functional CTDs, the minimal distance between
two mutations had to be two heptad repeats (Liu et al., 2008;
Schwer et al., 2012) (Figures 1C and S1B).
CTD sequences were cloned into the expression vector
LS*mock (Meininghaus et al., 2000), which carries the hemagglu-306 Molecular Cell 61, 305–314, January 21, 2016 ª2016 Elsevier Inc.tinin (HA)-tagged mouse Rpb1 gene. A
point mutation (N793D) in Rpb1 confers
resistance to a-amanitin and allows
the chemical ‘‘knockout’’ and functional
replacement of endogenous Pol II (Barto-
lomei and Corden, 1987). Stably trans-
fected Raji cells expressed recombinant
Rpb1 (Figure S1C) and proliferated in the
presence of a-amanitin treatment (Fig-
ure S1D). Although the CTD variant cell
lines showed slightly reduced cell growth
compared to wild-type (WT) Raji cells,
their cell viability remained constantly
high (Figure S1D). Western blot analysis
showed that the recombinant wild-type
Pol II CTD (WTrec), Pol II CTD variantsM1 and M3, and endogenous Pol II CTD (WT) all showed similar
CTD phosphorylation levels of Y1, S2, S5, and S7 (Figure S1E). In
contrast, T4-P levels were reduced in bothCTD variants suggest-
ing that our changes in the CTD sequence either led to amasking
of the T4-P-specific antibody epitope or interfered with the
recruitment of T4-specific kinases or phosphatases. Additionally,
the expression of the recombinant Rpb1 protein resulted in a
higher abundance of the Pol IIA form, whereas the actively tran-
scribing Pol IIO form was detected in similar levels when
comparing the endogenous (WT)—and recombinant (WTrec,
M1 and M3)—expression system (Figure S1E).
For MS analysis, Rpb1 was purified by immunoprecipitation
(IP) using a combination of two phospho-CTD-specific anti-
bodies (a-S2P (3E10) and a-S5P (3E8)) or HA-tag-specific anti-
bodies. The CTD phospho-specific antibodies purified the
hyperphosphorylated Pol IIO form to an extent of 80%–90%
AC
B
Figure 2. Valid Phosphosite Assignment
by Determining Site Probability Thresholds
Using Synthetic CTD Peptide Library
(A) List of synthesized CTD peptides (JPT—Inno-
vative Peptide Solutions). 20 mono-, double- or
triple-phosphorylated (1P, 2P and 3P) peptides
were made. Corresponding phospho-residues are
shown in red.
(B) 1P- (left), 2P- (middle) and 3P- (right) synthetic
peptides were used to determine the corre-
sponding site probability threshold (92%, 88.5%
and 80%, respectively) at a false localization rate
(FLR) of 20%. The assigned thresholds set the filter
for valid phosphosite-determination through the
Proteome Discoverer plugin PhosphoRS.
(C) Total counts of detected 1P-, 2P-, 3P- and 4P-
di-heptad-long (left) and -tri-heptad-long (right)
peptides with or without a phosphosite filter.
See also Figure S2.(Figure 1D). The detection of the two main Rpb1 species (IIO-
and IIA-form) using Coomassie-stained SDS-PAGE served as a
quality control for efficient purification of recombinant Rpb1 (Fig-
ure 1E). The two different Pol II forms were separately excised
and subjected to in-gel cleavage, followed by TiO2-phospho-
enrichment and liquid chromatography coupled to tandem
mass spectrometry (LC-MS/MS) (Experimental Procedures).
Valid Phosphosite Assignments Using Site-Specific
Probability Thresholds Based on a Synthetic CTD
Peptide Library
The phosphosites in CTD peptides were mapped based on MS
data using PhosphoRS 2.0 (Thermo Scientific) (Taus et al.,
2011), which calculates the localization probabilities for all po-
tential phosphorylation sites. The false localization rate (FLR)
(Marx et al., 2013) was determined using 20 synthetic CTD
peptides, which were either mono-, di-, or tri-phosphorylated
(Figures 2A and 2B). We set an FLR of 20%, which led to site
probability thresholds of 92%, 88.5%, and 80% for mono-,
double- and triple-phosphorylated peptides, respectively (Fig-
ure 2B). CTD peptides had to be two or three heptads in length
for appropriate detection by our MS analysis. Accordingly, the
highest phosphosite coverage along the CTD was obtained
from the three mammalian CTD variants M1, M2, and M3, for
which only di- and tri-heptads are generated by tryptic cleavage
(Figures 1A andS2). Additionally, due to very similarmass countsMolecular Cell 61, 305–314between the Y-b1-ion and the PK-y2-ion
in MS2, we excluded Y1-P counts coming
from peptides containing both Y in posi-
tion 1 and terminal PK from the final data-
set (942 out of 20,220 phosphopeptides),
leading to lower detection levels for Y1
phosphorylation (Figures 1A and S2).
Similarly, due to the many mutations
made in the S7 position within all five
CTD variants, our MS data of S7 phos-
phorylation has to be considered as
incomplete.We detected up to four phosphosites in mammalian CTD pep-
tides, although peptides were predominantly mono- and di-
phosphorylated (Figure 2C). CTD variant M1 showed the highest
number of mapped phosphosites within the proximal part of the
CTDbecause it is only cleaved into di-heptad-long peptides (Fig-
ure 1C), which pass the phosphosite filter more often than the tri-
heptad-long peptides (Figure 2C). In contrast, the high number of
identical CTD peptides in the distal part of CTD variants M1, M2,
and M3 led to similar phosphosite coverage in this region (Fig-
ures 1A and S2). OurMS analysis confirmed that all five residues,
which were previously described as being phosphorylated
based on antibody reactivity, are indeed phosphorylated.
It also revealed that the five resulting phosphoresidues, Y1-P,
S2-P, T4-P, S5-P, and S7-P, are generally found along the entire
CTD (Figures 1A and S2).
Frequency of Mono- and Double-Phosphorylated CTD
Heptad Repeats
To determine the relative abundance among the mono (1P)- and
double (2P)-phosphorylated heptad repeats, consensus repeats
along the entire CTD from all five CTD variants were taken into
account. S2-P and S5-P predominated in mono-phosphorylated
repeats contributing 75% to the total phospho-counts (Fig-
ure 3A), reflecting the prevailing importance of these two phos-
phoresidues during the transcription of all coding and non-cod-
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Figure 3. Phosphorylation Patterns within
Neighboring CTD Residues
(A) (Left) Relative abundance of the five different
CTD phosphosites (1P) within mono-heptads in
human (blue) and yeast (red). (Right) Relative
abundance of all ten possible double-phosphosite
combinations (2P) within mono-heptads in
human (blue) and yeast (red). All repeats with the
sequence YSPTSPX (X = S, T, K, R, N, E, or G) were
included in the final dataset.
(B) Next-neighbor phosphorylation study of S2-P
and S5-P in human.
(C) Next-neighbor phosphorylation study of S2-P
and S5-P in yeast. Only doubly phosphorylated
CTD peptides were taken into account, and the
defined sequence area comprised10 to +10 CTD
residues.
See also Figure S3.heptad repeats didn’t exceed 5%, whereas T4-P heptad repeats
showed significantly higher counts with a relative abundance of
15% (Figure 3A). When analyzing double-phosphorylated hep-
tad repeats, all possible double-phospho (2P) combinations
(10 out of 10) were detected within single heptads (Figure 3A)
revealing the high diversity of different 2P-combinations found
within a single seven-amino-acid interval. However, the total
counts of 2P-heptad repeats were 30 times lower compared
to 1P-heptad repeats, suggesting that the parallel existence of
two phosphosites within a single heptad repeat seems to be a
rather temporary rare event in vivo (Figure S3A). Additionally no
triple-phosphorylated heptad repeats were found, indicating
that multiple phosphosites found in close proximity to each other
might lead to unfavorable structural changes due to strong
charge repulsions.
Specific Double-Phospho Signatures Prevail within
Neighboring CTD Residues
We next analyzed the co-occurrence of Y1-P, S2-P, T4-P, S5-P,
and S7-P with a second phosphorylated site in the same heptad
repeat or in the adjacent N- or C-terminal heptad repeats (Fig-
ures 3B and S3B). Only double-phosphorylated CTD peptides
were taken into account, and the defined sequence area
comprised 10 to +10 CTD residues. S2-P and S5-P predomi-
nantly coexisted with a second phosphorylation at the same po-308 Molecular Cell 61, 305–314, January 21, 2016 ª2016 Elsevier Inc.sition in the adjacent repeat (± 7 position).
Additionally, the combination S2-P/S5-P
frequently occurred within neighboring
repeats and with lower frequency also
within the same repeat (Figure 3B). The
predominance of 2P-combinations of
S2-P and S5-P marks coincides with
several, previously described, known
CTD binding motifs of mammalian CTD
interacting factors such as Mce1, SCP1,
SCAF8, or Pin 1 (Jasnovidova and Stefl,
2013). T4-P frequently co-occurred with
S2-P, S5-P or a second T4-P. Y1-P and
S7-P showed only a very low number ofphosphorylation events in our study (Figure S3B), although we
note that we underestimate Y1-P and S7-P occurrence due to
an ambiguity in the fragment masses derived from Y1-P contain-
ing peptides (Experimental Procedures) and several mutations
made in the S7 position, respectively. All in all, 2P-patterns that
were found along adjacent heptad repeats occurred more
frequently compared to 2P-signatures coexisting within the
same repeat, suggesting that the majority of CTD recognition
motifs of interacting protein factors might comprise more than
one heptad repeat in length.
Differences in CTD Phosphorylation Signatures
between Yeast and Mammals
To investigate the possible evolutionary conservation of CTD
phosphorylations, we extended our analysis to the yeast system.
Two yeast CTD variants, called Yst1 and Yst2, were generated
(Figures S3C–S3E). The CTD variant Yst2 led to a higher phos-
phosite coverage along the entire CTD (Figure S3F). As for the
mammalian CTD, all five phosphoresidues were detected (Fig-
ure S3F). In mono-phosphorylated heptads, S5-P was by far
the most frequently detected phosphosite, whereas S2-P was
less abundant, in contrast to observations for the mammalian
CTD (Figure 3A). The higher S5-P/S2-P ratio for the yeast CTD
may result from the dramatically different gene lengths in yeast
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Figure 4. Phosphorylation Profile of All 52 CTD Repeats in Mammals
Comparison of the phosphorylation profile of all 52 CTD repeats in CTD variant
M1 (top) and M3 (bottom). Total counts of un-phosphorylated (white), mono-
phosphorylated (dark gray), and double-phosphorylated (light gray) counts of
each CTD repeat are shown. Total counts of phosphosites Y1-P (red), S2-P
(blue), T4-P (green), and S5-P (purple) within each repeat are shown. Y1-P
counts are under-represented in distinct repeats due to data exclusion from
Y1-P-false-positive biased peptides. S7-P counts were excluded due to many
amino acid substitutions at position 7. No data are shown for repeat 2, which is
split in half after trypsin digest due to an R residue at position 4.shorter in yeast and, thus, on average there are more tran-
scribing, S2-phosphorylated polymerases on genes in human,
whereas S5-P levels might be similar in yeast and human
because this phosphorylation is restricted to the 50-end of genesMo(Bataille et al., 2012). Y1-P and S7-P heptad repeats displayed
comparable low counts in both species. Surprisingly, T4-P re-
peats showed a similar frequency to S2-P repeats (20%
each) (Figure 3A), although no biological function of T4-P in yeast
has been described so far.
In yeast, all four possible 2P combinations with S7-P being one
of the two phosphosites were non-detectable (Figure 3A), which
may be explained by the low numbers of S7 residues found in
the two yeastCTDvariants. Similar tomammals, yeast 2P repeats
were found much less frequently compared to 1P repeats (15
times lower) (Figure S3A). However, doubly phosphorylated
repeats apparently reflect polymerase intermediates that are
functional at certain stagesof transcription. Forexample, thedou-
ble-phosphorylation Y1-P/S2-Pwas themost frequently detected
2P signaturewithin single yeast CTD repeats (Figures 3A and 3C),
although the total count numbers were rather low (34 counts).
Within adjacent repeats, we predominantly detected the co-exis-
tence of S5-Pmarks (200 counts) (Figure 3C) that correspond to
the known binding pattern of the capping enzyme Cgt1 (Jasnovi-
dova and Stefl, 2013). The second most abundant 2P signature
along neighboring repeats in yeast was S2-P/S5-P (25 counts),
in which S5-P was located at the N-terminal to S2-P (Figure 3C),
whereas in mammals, S2-P combined similarly frequently with
an N- or a C-terminal S5-P. Surprisingly, compared to the
mammalian CTD, adjacent yeast CTD repeats showed no S2-P/
S2-P 2P-patterns (Figure 3C). This finding might result from the
design of our yeast CTD variants, in which several S2 residues
were replaced by other amino acid residues (Figure S3C).
Phosphorylation Profile of All 52 CTD Repeats
Next, we analyzed the distribution of phosphorylations over all
52 mammalian CTD repeats. We first compared the heptad-spe-
cific phosphorylation profiles between CTD variants M1 and M3.
The distal CTD repeats 32–52 showed a highly similar distribu-
tion in the relative abundance of phosphosites between CTD
variants M1 and M3 (Figure 4), likely due to the high peptide
sequence overlap in this region (Figure 1C; Figure S1B). In
contrast, the fragmentation of the proximal part of the CTD
from variant M1, resulting in only di-heptad-long peptides and
our ability to clearly distinguish and detect Y1-P (except for
repeat 7), led to a more uniform and reliable phosphosite distri-
bution and to higher phospho-counts in this region compared
to CTD variant M3 (Figure 4).
By analyzing the heptad-specific phosphorylations in CTD
variant M1 in more detail, the proximal consensus CTD part
(repeats 4–31) displayed a very similar distribution in the relative
abundance of the phosphorylations (Figure 4). S2-P and S5-P
showed constant high counts, whereas Y1-P and T4-P were de-
tected less frequently. S5-P was the predominant phosphosite in
repeats 3, 32, and 38, which all contain a threonine instead of
serine at position 2 and glutamine (Q) or alanine (A) at position
4 (Figure 4). The distal part of the CTD showed higher variations
in its phosphorylation profile as well as lower total phosphoryla-
tion counts, mainly due to the absence of S2-P in repeats 32, 34,
36, 41, 43, and 48 (Figure 4). This can at least partly be explained
by our exclusion of Y1-P in these repeats, due to a fragment
ion mass ambiguity. Indeed, distal CTD repeats 39, 40, 42,
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Figure 5. S2-P Is Strongly Reduced in the
CTD upon CDK9 Inhibition
(A) Comparative study of phosphorylation profiles
of all CTD repeats between control (ctr) and
flavopiridol-treated samples of CTD variant M1
(n = 4) (HC: heptad counts; PA: phospho-acceptor
counts).
(B) Increase/decrease (+10/20 counts) of S2-P,
S5-P, and T4-P comparing total counts between
control samples and flavopiridol samples for each
repeat. Y1-P counts are under-represented in
distinct repeats due to data exclusion from Y1-P-
false-positive biased peptides. S7-P counts were
excluded due to many amino acid substitutions at
position 7.
See also Figure S4.assignments, showed comparable phosphorylation profiles as
found in the proximal CTD consensus repeats (Figure 4). Conse-
quently, the mammalian CTD seems to be phosphorylated in
a rather uniform manner along its entire sequence with S2-P
and S5-P being the two predominant phosphosites in almost
all CTD repeats. Nevertheless, we cannot exclude that more
diverse heptad specific phosphorylation profiles might exist
within distinct subpopulations of RNA Pol II.
S2-P Is Strongly Reduced within the CTD upon CDK9
Inhibition
Finally, we tested whether our MS approach was able to detect
physiological changes in CTD phosphorylation. To do this, we
treated the cells with the CDK9 inhibitor flavopiridol, which was
reported to decrease S2-P levels (Chao et al., 2000; Chao and
Price, 2001). Using western blot analysis, we confirmed a strong
decrease in the signal intensity of S2-P after 2.5 hr of flavopiridol310 Molecular Cell 61, 305–314, January 21, 2016 ª2016 Elsevier Inc.treatment and a strong reduction of the
hyper-phosphorylated IIO-form of Rbp1,
whereas the phosphorylation signals for
S5 and S7 remained constant over 6 hr
(Figures S4A and S4B). Consistent with
this, our MS analysis also revealed a
decrease in the total counts of S2-P for
the majority of CTD repeats of M1 in the
flavopiridol-treated samples (Figures 5A
and 5B). A strong reduction of S2-P was
observed in almost all S2-P-containing
repeats showing that CDK9 inhibition led
to phosphosite-specific changes along
the CTD. In contrast, S5-P and T4-P
counts were only very slightly reduced
or even showed increased signals upon
CDK9 inhibition (Figures 5A and 5B). The
majority of repeats retained comparably
high phospho-counts (Figure 5A). Sur-
prisingly, we did not detect in vivo
changes in S5-P upon flavopiridol treat-
ment, although it was reported that
CDK9 phosphorylates S5 in vitro (Bo¨sken
et al., 2014; Czudnochowski et al., 2012),emphasizing a need for assessing the specificity of CTD kinases
and phosphatases in vivo.
DISCUSSION
Studies of phosphorylation states of the CTD of Pol II have
been exclusively performed using CTD-phospho-specific anti-
bodies. Our combined genetic and mass spectrometric
approach overcomes the limitations of antibody detection
and offers a comprehensive map of CTD phosphorylations
that allowed the detection of the prevailing phosphorylation
patterns in CTD heptad repeats. Due to the highly repetitive
sequence of the CTD, we were faced with several technical
challenges. First, we introduced a series of lysines or arginines
to allow the tryptic cleavage of the CTD into very short pep-
tides, which do not extend the length of four heptad repeats
(Figures 1C and S1B). Longer peptides are multiply charged
and are therefore not suitable for MS analysis (Steen and
Mann, 2004). Second, to precisely map phosphosites by LC-
MS/MS, we replaced or introduced additional amino acids,
which generated peptides with a unique mass for MS2 analysis
(Figures 1C and S1B). Third, we introduced a phosphopeptide
enrichment step by TiO2, taking advantage of the strong affin-
ity of negatively charged phosphate groups toward metal ions
(Larsen et al., 2005). Fourth, we used a training set of synthetic
phosphopeptides (Figure 2A) to determine the false discovery
rate of the assigned phosphosites. The site probability
threshold varied depending on the amount of introduced phos-
phorylation sites per peptide (Figure 2B). The fact that pep-
tides with two or three heptad repeats contain up to 9–14
potential phospho-acceptor sites impedes the correct phos-
phosite assignment. The probability further decreases with
longer peptides. Fifth, the design of five CTD variants allowed
us to obtain a large spectrum of different CTD peptides based
on sequence and length.
This comprehensive map of CTD phosphorylations in yeast
and mammals revealed that the five CTD phosphoresidues
are generally distributed along the entire CTD in both species,
albeit with different frequencies. S2-P and S5-P prevailed, sug-
gesting that these two phosphosites play a predominant role
during transcription. Y1-P and T4-P were present at lower levels
in our MS approach indicating that these CTD residues might
play an important role that is restricted to more specific func-
tions. We should emphasize that Y1-P counts are underesti-
mated in our study due to technical reasons. Consequently,
our Y1-P data cannot be used to support or disprove a function
of Y1-P in initiation or elongation control (Descostes et al., 2014;
Mayer et al., 2012). Moreover, we cannot rule out that the found
ratios between the different phosphosites might change when
analyzing specific subpopulations of RNA Pol II. Another com-
mon finding in both species was that the CTD is not heavily
phosphorylated. In more detail, double-phosphorylated CTD re-
peats were rarely found suggesting that multiply phosphory-
lated repeats more likely represent polymerase intermediates
that are functional at certain stages of transcription. Neverthe-
less, predominant 2P signatures were found within neighboring
CTD residues that might serve as recognition motifs of CTD in-
teracting factors and thereby help to orchestrate the transcrip-
tion cycle as well as transcription-coupled RNA processing
events. The approach also enables a more detailed assessment
of alterations in CTD phosphorylations during cellular physi-
ology as shown by our CDK9 inhibition experiment in the
mammalian CTD. In more detail, the strong reduction of S2-P
within the CTD through the inhibition of the CTD S2 kinase
CDK9 demonstrates that our combined genetic-LC-MS/MS
strategy can detect heptad-specific changes in phosphorylation
states within the CTD.
A critical step for the successful application of this protocol
was the design of CTD variants, which enables cell growth
and proliferation. The minimal length and sequence require-
ments of CTD that are needed for normal cell viability have not
been determined yet for mammalian cells. However, our suc-
cessful design of five stable CTD variants revealed the high plas-
ticity of the mammalian CTD and confirmed that substantial
manipulation of CTD is possible (Bartolomei et al., 1988).MoConsequently, our established CTD variants are a powerful
tool to gain deeper insights into CTD heptad-specific phosphor-
ylation after the knock out of cellular kinases or phosphatases.
For example, by establishing specific CTD kinase analog sensi-
tive mammalian cell lines (Bartkowiak et al., 2015; Laitem et al.,
2015) using the genomic engineering tool CRISPR/Cas (Cong
et al., 2013; Fu et al., 2013; Mali et al., 2013), CTD-specific ki-
nase knockdowns will possibly link different CTD subregions
to specific kinase activities. In the future, it may also allow us
to monitor changes in CTD phosphorylation after activation of
specific signaling pathways. Finally, analysis of the heptad spe-
cific phosphorylation patterns of RNA Pol II subforms that are
located at different positions along genes during the transcrip-
tion cycle might lead to a better understanding of their functional
properties.
EXPERIMENTAL PROCEDURES
Plasmids and Mammalian Cell Culture
CTD sequences of WTrec and CTD variants M1-M5 were synthesized
(GeneArt) using human codon optimization and cloned into the LS*mock
vector (Meininghaus et al., 2000). All final constructs were sequenced before
usage. Full-length Rpb1 expression vectors (WTrec, M1–M5) were transfected
into the Epstein-Barr-virus-positive Burkitt lymphoma cell line Raji by electro-
poration (10 mg plasmid DNA/107 cells; 960 mF; 250 V). Selection of a positive
polyclonal cell line was achieved by the addition of G418 (1 mg/ml) for
14–20 days to recover a viability of 95%. Established cell lines were
maintained in RPMI 1640 medium supplemented with 10% fetal calf serum,
1% penicillin streptomycin (Gibco, Invitrogen), 2 mM L-glutamine (Gibco,
Invitrogen), and 2 mg/ml a-amanitin at 37C with 5% CO2.
Yeast Culture
The newly synthesized CTD variants (GeneArt) Yst1 and Yst2 were cloned into
the pRS315-Rpb1 plasmid (Sun et al., 2012). After ligation, the product was
transformed into XL1 blue cells (Stratagene). Positively sequenced Rpb1
mutant plasmids were then transformed into the BY Drpb1 pRS316-Rpb1
strain and plated onto -leu/-ura plates (0.69% [w/v] yeast nitrogen base,
0.067% [w/v] drop-out -leu/-ura, 2% [w/v] glucose, 2% [w/v] agar) to select
for pRS315 and pRS316 plasmids. Single clones were then transferred
to -leu plates to preserve only the pRS315 plasmid. Spot dilutions of single
clones were spotted onto YPD and 5-FOA plates (SC [-ura], 0.01% [w/v] uracil.
0.2% [w/v] 5-FOA, 2% [w/v] agar) in parallel. Strains that grew on 5-FOA plates
only contained the correct pRS315 shuffle plasmid. Plates were generally incu-
bated at 30C, and 5-FOA plates were incubated at 25C. Single clones
from 5-FOA plates were sequenced again to ensure that the strain did not
change its CTD sequence by self-recombination. The TAP tag on Rpb3 was
introduced by homologous recombination of a PCR product amplified





A 2x laemmli buffer was added to protein samples, which were then separated
by SDS-PAGE (6.5% gel) and transferred to a nitrocellulose membrane (GE
Healthcare) afterward. Unspecific binding of antibodies was blocked by incu-
bation with 5% milk in TBS-T before being incubated with primary antibodies
diluted in blocking solution. The primary antibodies we used are as follows:
a-Rpb1 (POL 3/3); a-HA (3F10, Roche); CTD phospho-specific antibodies
a-Y1-P, S2-P, T4-P, S5-P, and S7-P (5G9, 3D12, 3E10, 6D7, 3E8, and 4E12)
(Chapman et al., 2007); and a-tubulin (T6557) (Sigma). Afterward, the mem-
branes were either incubated with IRDye-labeled, secondary antibodies
against rat (680 nm; Alexa, Invitrogen) and mouse (800 nm; Rockford, Biomol)
and analyzed using an Odyssey Imaging System (Li-Cor) or they were stainedlecular Cell 61, 305–314, January 21, 2016 ª2016 Elsevier Inc. 311
with HRP-conjugated secondary antibodies against rat (Sigma) or mouse
(Promega) and revealed by enhanced chemiluminescence.
Purification of Recombinant Rpb1 Protein from Mammalian Cells
All of the following stepswere performed at 4C. 33 108 Raji cells were lysed in
10 ml IP-lysis buffer (50 mM Tris-HCl [pH 8.0], 150mM NaCl, 1% NP-40
[Roche], 1x PhosSTOP [Roche], 1x protease inhibitor cocktail [Roche]) and
incubated for 30 min on an end-over-end shaker. Samples were sonified
(Sonifier 250 [Branson], 3 3 20 pulses, output 7, duty cycle 70%), incubated
for 1 hr on an end-over-end shaker, and centrifuged (10,500 3 g, 15 min).
Cell lysates were incubated with antibodies, coupled protein G-sepharose
beads (20–40 mg of either aHA [3F10, Roche] or aSer2-P [3E10]/ aSer5-P
[3E8] in a 1:1 ratio) on an end-over-end shaker overnight. Beads were washed
three times with IP-lysis buffer and subsequently boiled in 2x laemmli buffer at
95C for 8 min. The released proteins were loaded onto an SDS-PAGE gel. Af-
ter separation by electric current, gels were stained with EZBlue Coomassie
Brilliant Blue G-250 (Sigma).
Purification of Recombinant Rpb1 Protein from Yeast
2 l YPD media were inoculated with 500 ml of a pre-culture of BY Drpb1
pRS315-Rpb1-CTD-variant Yst1 or -variant Yst2 with a TAP-tag on Rpb3
and grown to OD600 3.0–3.5 (30
C/160 rpm) overnight. Cells were harvested,
and they were washed once with 500 ml water and once with 25 ml TAP lysis
buffer (LB; 50 mM Tris-HCl [pH 7.5], 100 mM NaCl, 0.15 mM MgCl2, 0.15%
NP40). Pellets were flash frozen in liquid nitrogen and stored at 80C. The
following steps were all performed at 4C: After thawing, an equal volume
of LB containing protease inhibitors (0.28 mg/ml leupeptin, 1.37 mg/ml
pepstatin A, 0.17 mg/ml PMSF, 3.3 mg/ml benzamidine) and 1x PhosSTOP
(Roche) was added to the pellet. The same volume of glass beads was added
to the cell suspension. Cell lysis was performed in 15 ml Falcon centrifuge
tubes using the FastPrep24 (MP) and the 12x15 adapter for 3 3 30 s at
5.5 m/s with 3 min breaks on ice. Lysates were centrifuged at 4,000 rpm for
10 min. The supernatant was transferred to pre-cooled ultracentrifugation
tubes and centrifuged at 27,000 rpm for 1 hr. The lysate was transferred
from underneath the fatty top phase to new tubes. 200 ml Protein G Dynabeads
Magnetic Beads (Invitrogen), pre-coated with 110 ml rabbit IgG (1.5 mg/ml,
Sigma/Aldrich), were added to the cell extract and incubated for 1 hr on a
turning wheel (8 ml cell extract per 200 ml beads). TAP-tagged proteins were
eluted by addition of 70 ml LB and 2 ml TEV protease (2 mg/ml). The beads
were re-suspended by vortexing, and the suspension was incubated on a
rotating wheel for 90 min. Subsequently, the supernatant was collected fol-
lowed by the addition of 30 ml LB to the beads (additional elution fraction).
25 ml SDS-PAGE loading buffer (5x) were added to complete the elution, and
the suspension was boiled for 2 min at 95C. Protein samples were separated
by SDS-PAGE according to their size, using pre-cast NuPAGE 4%–12% Bis-
Tris gels (Life Technologies) in a Novex Mini-Cell chamber (Invitrogen) at 160–
200V. Gels were subsequently stained using Instant Blue (Expedeon).
In-Gel Cleavage and Phosphopeptide Enrichment
A standardized protocol was used for in-gel digestion, including four main
steps: (1) de-staining, (2) cysteine reduction and alkylation, (3) tryptic cleav-
age, and (4) extraction of the generated peptides. Subsequent to in-gel cleav-
age, the extracted peptides were subjected to phosphopeptide enrichment.
The sample volume was reduced to 5 ml by speed-vac and afterward dis-
solved in 100 ml loading buffer (80% acetonitrile, 5% TFA, and 1M glycolic
acid). 10 ml of TiO2 bead solution (0.03 mg/ml TiO2 beads in 100% ACN)
were added, and the samples were incubated on a shaker at room tempera-
ture for 10 min. After a short centrifugation, two washing steps were per-
formed (washing buffer 1: 80% acetonitrile, 1% TFA; washing buffer 2: 10%
acetonitrile, 0.2% TFA). Afterward, the supernatant was removed completely
and the beads were dried for at least 10 min. For elution of the bound phos-
phopeptides, 50 ml elution buffer (40 ml ammonia solution [28%] in 960 ml
H2O) was added and the samples were incubated on the shaker at room tem-
perature for 10 min. The supernatant containing the phosphopeptides was
transferred to a new tube, and the sample volume was reduced to 5 ml using
a speed-vac. 30 ml 0.1% formic acid (FA) was added, and the samples were
stored at 20C until measured.312 Molecular Cell 61, 305–314, January 21, 2016 ª2016 Elsevier IncSynthetic Peptide Library
20 Maxi SpikeTides L peptides (amount: 0.5 mg) were synthesized by JPT-
Innovative Peptide Solutions. All peptides were heavy isotope-labeled on their
C-termini (K) and were dissolved in DMSO (stock solution: 1 nmol/ml). Peptides
were further diluted adding 100% ACN before being measured (working
solution: 1.5 pmol/ml).
Liquid Chromatography Coupled to Tandem Mass Spectrometry
For LC-MS/MS, TiO2-enriched phosphopeptides were automatically injected
into an Ultimate 3000 HPLC system (Dionex), desalted online (300 mm i.d. 3
5 mm cm, PepMap100 C18 5 mm, 100 A˚, Dionex), and separated on an analyt-
ical column (75 mm i.d. 3 10 cm, packed in house with ReproSil-Pur C18 AQ
2.4 mm, Dr. Maisch) using a 60 min gradient from 5% to 30% acetonitrile in
0.1% formic acid. The effluent from the HPLC was directly electrosprayed
into a LTQ Orbitrap XL mass spectrometer (Thermo), operated in data-depen-
dent mode to automatically switch between full-scan MS and MS/MS acquisi-
tion. Survey full-scan MS spectra (from m/z 300 to 2000) were acquired in the
Orbitrap with a resolution of R = 60,000 at m/z 400 (after accumulation to a
‘‘target value’’ of 500,000 in the linear ion trap). The three most intense peptide
ions with a charge state higher than 1 and lower than 4 were sequentially iso-
lated to a target value of 10,000 and fragmented in the linear ion trap by colli-
sion-induced dissociation (CID). Multistage activation was selected as the
fragmentation method to automatically select and fragment the ions originated
from the loss of one or two phosphate groups from the parent ion. For all
measurements with the Orbitrap mass analyzer, three lock-mass ions from
ambient air (m/z = 371.10123, 445.12002, and 519.13882) were used for inter-
nal calibration (Olsen et al., 2005). Typical mass spectrometric conditions were
the following: spray voltage, 1.5 kV; no sheath and auxiliary gas flow; heated
capillary temperature, 200C; and normalized collision energy, 35% for CID
in LTQ. The ion selection threshold was 10,000 counts for MS2. An activation
q = 0.25 and activation time of 30mswere used. Mass spectrometry data were
analyzed using Proteome Discoverer 1.4/PhosphoRS 2.0 (Taus et al., 2011)
(MS tol., 10 ppm; MS/MS tol., 0.8 Da, Variable modifications, oxidation [M]
and phosphorylation [S,T,Y]; fixed modifications, carbamidomethyl [C]; FDR
peptide, 0.01).
Data Analysis
Proteome Discoverer output was processed for downstream analyses
and visualizations using R (http://www.r-project.org). All data obtained from
the same variant and same experimental condition were pooled. Only peptides
with a search engine rank of 1 were considered for downstream analysis.
Phosphosite assignments were made by comparing site-specific phosphory-
lation probabilities, as calculated by PhosphoRS with the probability thresh-
olds defined by analyzing synthetic peptides as follows: MS output of synthetic
peptide runs were processed in the same way as for the biological samples.
We determined the fraction of false-positive phosphorylation assignments
by calculating the ratio of unexpected, false-positive versus total phosphory-
lation assignment as a function of a range of threshold levels on the
PhosphoRS site probabilities. For this procedure, we separated the data
based on the total number of phosphorylation events per peptide (Ptotal)
because the site probabilities were inversely correlated with Ptotal. Accord-
ingly, we defined specific thresholds for each level of Ptotal to yield a false-pos-
itive rate of 20%. In the biological samples, PhosphoRS sites not passing this
filter were marked as ambiguous. In addition, peptides with both Y1P and
C-terminal PK were removed. Context-independent reporting of site-specific
phosphorylation included only unambiguous assignments. Phosphorylation
pattern analysis and context-dependent reporting excluded instances in
which ambiguous sites were present in their respective context. For example,
analysis of phosphorylation patterns in mono-heptads included only heptads
that did not have ambiguous phosphorylation calls.
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